title: New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
abstract: Over the last few years a number of new different compounds have been developed. They include phosphatidylinositol 3-kinase (PI3-K) inhibitors. Deregulation within the PI3-K pathway is common in head neck squamous cell carcinoma (HNSCC) and it represents a growing area of research. PI3-K inhibitors, including BKM120, PX-866 and BYL719, are being tested in several phase I and phase II studies in patients with locally advanced, recurrent or metastatic disease. This review provides an update of published clinical trials and highlights the challenges of PI3-K inhibitors in HNSCC.
authors.affiliation: Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. Electronic address: fradefelice@hotmail.it.
authors.forename: Francesca
authors.initials: F
authors.lastname: De Felice
authors.affiliation: Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: Teresa
authors.initials: T
authors.lastname: Guerrero Urbano
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000077195:Squamous Cell Carcinoma of Head and Neck
chemical_list: D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors
keywords: Head and neck cancer; Locally advanced disease; PI3-K inhibitors; Radiotherapy; Recurrence; Squamous cell; Survival